Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T18:46:05.928Z.
Calculation as of: 2026-10-06T18:46:05.928Z.
Quote observation: 2026-10-06T18:44:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47fe9b5a4b5325aa2b63eefeab4e4f99d65252ab4bc117be38c834a5b01498bd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Coya Therapeutics, Inc.
Market Cap
$116.58M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Coya Therapeutics, Inc. (COYA) | $116.58M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.02M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.06M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | N/A |
| Genelux Corporation (GNLX)vs › | $114.34M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $119.23M | N/A |
| BGM Group Ltd. (BGM)vs › | $119.26M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $113.02M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $119.38M | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.94M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
